Companies: 48,687 Total Market Cap: 125800178376592.40

AbbVie

NYSE: ABBV
Healthcare Drug Manufacturers - General
Rank #26
Market Cap 342.01 B
Volume 5.82 M
Price 193.34
Change (%) 0.90%
Country or region United States United States

AbbVie's latest marketcap:

342.01 B

As of May 2, 2025, AbbVie's market capitalization has reached $342.01 B. According to our data, AbbVie is the 26th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 342.01 B
Revenue (ttm) 57.37 B
Net Income (ttm) 4.16 B
Shares Out 1.77 B
EPS (ttm) 2.34
Forward PE 15.17
Ex-Dividend Date April 15, 2025
Earnings Date April 25, 2025
Market Cap Chart
Data Updated: May 2, 2025

AbbVie's yearly market capitalization.

AbbVie has seen its market value grow from $84.01 B to $339.55 B since 2013, representing a total increase of 304.16% and an annual compound growth rate (CAGR) of 13.13%.
Date Market Cap Change (%)
April 28, 2025 $339.55 B 8.13%
December 31, 2024 $314.02 B 14.77%
December 29, 2023 $273.61 B -4.27%
December 30, 2022 $285.80 B 19.4%
December 31, 2021 $239.37 B 26.54%
December 31, 2020 $189.17 B 44.48%
December 31, 2019 $130.93 B -5.58%
December 31, 2018 $138.67 B -10.18%
December 29, 2017 $154.39 B 51.71%
December 30, 2016 $101.76 B 5.08%
December 31, 2015 $96.84 B -7.12%
December 31, 2014 $104.26 B 24.1%
December 31, 2013 $84.01 B

Company Profile

About AbbVie Inc.

AbbVie Inc. is a leading research-based biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Founded in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing complex health challenges across multiple therapeutic areas.

Key Product Offerings

  • Immunology: Humira (autoimmune diseases), Skyrizi (psoriasis), Rinvoq (inflammatory diseases)
  • Oncology: Imbruvica (blood cancers), Venclexta/Venclyxto (blood cancers), Elahere (various cancers), Epkinly (lymphoma)
  • Neuroscience: Botox Therapeutic (neurologic diseases), Vraylar (schizophrenia, bipolar disorder), Ubrelvy (migraine), Qulipta (migraine)
  • Eye Care: Ozurdex (eye diseases), Lumigan/Ganfort, Alphagan/Combigan (glaucoma), Restasis (tear production)
  • Gastroenterology: Mavyret/Maviret (hepatitis C), Creon (pancreatic enzyme therapy), Linzess/Constella (IBS with constipation)

Additional Therapeutic Solutions

AbbVie also provides a range of products in aesthetics, including facial injectables, regenerative medicine, body contouring, and skincare. The company continues to expand its portfolio through cutting-edge research and strategic collaborations.

Frequently Asked Questions

As of May 2, 2025, AbbVie (including the parent company, if applicable) has an estimated market capitalization of $342.01 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

AbbVie global market capitalization ranking is approximately 26 as of May 2, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United States
Founded 2012
IPO Date n/a
Employees 55,000
CEO Robert Michael
Sector Healthcare
Industry Drug Manufacturers - General
Address 1 North Waukegan Road
North Chicago, Illinois 60064-6400
United States
People Also Watch
LLY
794.10 0.90%
JNJ
154.46 0.90%
NVO
65.60 0.90%
SWX-ROG
329.53 0.90%